TAK-285 Size:Solid 10 mg Selective inhibition of JNK by

Selective inhibition of JNK by CC-930 exerted potent antifibrotic effects in vitro and in different models in vivo

ZLN005 was used at 10-20 µM final concentration in various in vitro assays

a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform

) shows significant antitumor effect in the KMS11-bearing mice model

InChiKey: DYGBNAYFDZEYBA-UHFFFAOYSA-N

TAK-285 Size:Solid 10 mg Selective inhibition of JNK byTAK 285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK 285 is currently being developed by Takeda. TAK 285 was found to be well tolerate in Phase I trials. Absorption of TAK 285 was rapid after oral dosing, and plasma exposure at steady state increased in a dose proportional fashion for doses ranging from 50 to 300 mg b. i. d. A partial response was observed